组蛋白去乙酰化酶抑制剂在肾间质纤维化中的应用
Application of Histone Deacetylase Inhibitors in Renal Interstitial Fibrosis.
作者信息
Nie Ling, Liu Yong, Zhang Bo, Zhao Jinghong
机构信息
Department of Nephrology, Institute of Nephrology of Chongqing and Kidney Center of PLA, Xinqiao Hospital, Army Medical University (The Third Military Medical University), Chongqing, China.
出版信息
Kidney Dis (Basel). 2020 Jul;6(4):226-235. doi: 10.1159/000505295. Epub 2020 Mar 26.
BACKGROUND
Renal interstitial fibrosis is characterized by the accumulation of extracellular matrix proteins, which is a common feature of chronic kidney diseases.
SUMMARY
Increasing evidence has shown the aberrant expression of histone deacetylases (HDACs) in the development and progression of renal fibrosis, suggesting the possibility of utilizing HDAC inhibitor (HDACi) as therapeutics for renal fibrosis. Recent studies have successfully demonstrated the antifibrotic effects of HDACis in various animal models, which are associated with multiple signaling pathways including TGF-β signaling, EGRF signaling, signal transducer and activator of transcription 3 pathway, and JNK/Notch2 signaling. This review will focus on the utilization of HDACi as antifibrotic agents and its relative molecular mechanisms.
KEY MESSAGES
HDACis have shown promising results in antifibrotic therapy, and it is rational to anticipate that HDACis will improve clinical outcomes of renal fibrosis in the future.
背景
肾间质纤维化的特征是细胞外基质蛋白的积累，这是慢性肾脏病的一个常见特征。
总结
越来越多的证据表明组蛋白去乙酰化酶（HDACs）在肾纤维化的发生和发展中表达异常，提示利用HDAC抑制剂（HDACi）作为肾纤维化治疗药物的可能性。最近的研究已成功在多种动物模型中证实了HDACi的抗纤维化作用，这与包括转化生长因子-β信号通路、表皮生长因子受体（EGRF）信号通路、信号转导子和转录激活子3信号通路以及JNK/Notch2信号通路在内的多种信号通路相关。本综述将聚焦于HDACi作为抗纤维化药物的应用及其相关分子机制。
关键信息
HDACi在抗纤维化治疗中已显示出有前景的结果，并且有理由预期HDACi未来将改善肾纤维化的临床结局。
Zotero 插件